Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brachytherapy + ADT for Recurrent Prostate Cancer
NCT00684905Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2000
- Primary completion
- Oct 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leuprolide and bicalutamide in prostate cancer (PCa), sponsored by Mayo Clinic. Primary endpoints: Feasibility of interstitial brachytherapy combined with androgen-deprivation therapy, Patient tolerance of interstitial brachytherapy combined with androgen-deprivation therapy and 2 more. Started Apr 2000; status: completed.
02
Drugs
leuprolidebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00684905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684905.